When the FDA needed help last year to figure out the contamination problem with Chinese heparin, the FDA turned to MNTA, not Teva (#msg-28748329).
I think this is a major point that really can't be emphasized enough. And it's one of the main reasons I decided to invest in MNTA. The fact that they were able to assist the FDA and identify the contaminated heparin can only help in giving the FDA reassurances with respect to MNTA's technology. That should give MNTA a clear leg up on the competition.